On Monday, Shares of Yahoo! Inc. (NASDAQ:YHOO), subtract -0.19% and shut at $41.11 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $40.94 and $41.48. The business’ commercial center capitalization is $38.98 Billion with the aggregate fabulous loads of 954.12 million. Yahoo! Inc., together with its auxiliaries, provides search and display advertising services on Yahoo properties and associate sites worldwide. The company offers Yahoo Search that serves as a guide for users to discover information on the Internet; Yahoo Mail, which connects users to the people and content; and Yahoo Messenger, an instant messaging service, which facilitates users to connect, communicate, and share experiences in real-time. It also provides digital content products, counting Yahoo News, which gives users to discover, consume, and engage around the news, content, and video; Yahoo Sports, which serves audiences of sports enthusiasts; Yahoo Finance that offers a range of financial data, information, and tools; Yahoo Lifestyle to engage users passionate about style and fashion; and Tumblr, which provides a Web platform and mobile applications on iOS and android to create, share, and curate content, in addition to Tumblr messaging that facilitates users to engage with other users that share their same interests and passions. In addition, the company provides advertiser products, such as Yahoo Gemini, a marketplace for search and native advertising; and BrightRoll, which offers a suite of media-agnostic tools to facilitate advertisers, publishers, and partners connect with users across ad formats and devices.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), subtract -0.05% and shut at $56.73 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $56.40 and $56.85. The association’s commercial center capitalization is $94.94 Billion with the general uncommon loads of 1.67 billion. Bristol-Myers Squibb Company (BMY) recently declared new data to be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria from December 4-7. Among the key data to be presented, studies evaluating Opdivo (nivolumab) monotherapy and in combination with Yervoy (ipilimumab) in two types of lung cancer highlight the company’s commitment to addressing high unmet medical needs.
Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb, commented, “We believe Immuno-Oncology combinations may assist improve outcomes for patients with lung cancer and have a strong scientific rationale for studying the Opdivo and Yervoy combination therapy. At the WCLC meeting, we will share data investigating this regimen in first-line non-small cell lung cancer and formerly treated small cell lung cancer, in addition to other important data from our broad thoracic development program.”